​

Monopar Therapeutics (MNPR) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

MNPR Stock Forecast

Monopar Therapeutics (MNPR) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $110.14, with a high of $142.00 and a low of $85.00. This represents a 37.81% increase from the last price of $79.92.

- $30 $60 $90 $120 $150 High: $142 Avg: $110.14 Low: $85 Last Closed Price: $79.92

MNPR Stock Rating

Monopar Therapeutics stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 1 Strong Buy (7.69%), 10 Buy (76.92%), 2 Hold (15.38%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 0 2 10 1 Strong Sell Sell Hold Buy Strong Buy

MNPR Price Target Upside V Benchmarks

TypeNameUpside
StockMonopar Therapeutics37.81%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts31012
Avg Price Target$127.33$100.80$88.92
Last Closing Price$79.92$79.92$79.92
Upside/Downside59.32%26.13%11.26%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25281--11
Sep, 25241--7
Aug, 25241--7
Jul, 25231--6
Jun, 25211--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 13, 2025Etzer DaroutBarclays$125.00$87.8242.34%56.41%
Oct 06, 2025Raymond James$142.00$99.3942.87%77.68%
Oct 02, 2025Oppenheimer$115.00$84.7335.73%43.89%
Sep 29, 2025H.C. Wainwright$105.00$76.6337.02%31.38%
Sep 25, 2025Keay NakaeChardan Capital$85.00$72.7016.92%6.36%
Sep 25, 2025Biren AminPiper Sandler$95.00$72.7030.67%18.87%
Sep 09, 2025Jeet MukherjeeBTIG$87.00$44.9393.63%8.86%
Sep 02, 2025Raymond James$80.00$33.93135.78%0.10%
Aug 26, 2025H.C. Wainwright$70.00$30.61128.68%-12.41%
Nov 19, 2024Justin WalshUBS$37.00$19.0194.63%-53.70%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 13, 2025BarclaysOverweightinitialise
Oct 06, 2025Raymond JamesStrong BuyStrong Buyhold
Oct 02, 2025OppenheimerOutperformOutperformhold
Sep 29, 2025H.C. WainwrightBuyBuyhold
Sep 25, 2025Piper SandlerOverweightOverweighthold
Sep 24, 2025BTIGBuyBuyhold
Sep 24, 2025Cantor FitzgeraldOverweightOverweighthold
Sep 23, 2025Lake StreetBuyinitialise
Sep 09, 2025BTIGBuyinitialise
Sep 03, 2025OppenheimerOutperforminitialise

Financial Forecast

EPS Forecast

$-450 $-350 $-250 $-150 $-50 $50 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.58$-411.23----
Avg Forecast$-3.30$-1.29$-2.38$-1.48$0.53$1.86
High Forecast$-3.30$-1.26$-1.27$0.70$3.17$1.86
Low Forecast$-3.30$-1.31$-3.49$-3.95$-3.69$1.86
Surprise %-82.42%31778.29%----

Revenue Forecast

$10M $23M $36M $49M $62M $75M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$14.52M$42.50M$70.72M
High Forecast---$14.52M$42.50M$70.72M
Low Forecast---$14.52M$42.50M$70.72M
Surprise %------

Net Income Forecast

$-20B $-15B $-10B $-5B $0 $5B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.40M$-15.59B----
Avg Forecast$-47.89M$-18.69M$-34.53M$-15.84M$-8.53M$26.99M
High Forecast$-47.89M$-18.35M$-18.42M$10.16M$46.00M$26.99M
Low Forecast$-47.89M$-19.03M$-50.65M$-57.32M$-53.55M$26.99M
Surprise %-82.45%83291.11%----

MNPR Forecast FAQ

Is Monopar Therapeutics stock a buy?

Monopar Therapeutics stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 10 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Monopar Therapeutics is a favorable investment for most analysts.

What is Monopar Therapeutics's price target?

Monopar Therapeutics's price target, set by 13 Wall Street analysts, averages $110.14 over the next 12 months. The price target range spans from $85 at the low end to $142 at the high end, suggesting a potential 37.81% change from the previous closing price of $79.92.

How does Monopar Therapeutics stock forecast compare to its benchmarks?

Monopar Therapeutics's stock forecast shows a 37.81% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Monopar Therapeutics over the past three months?

  • October 2025: 18.18% Strong Buy, 72.73% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is Monopar Therapeutics’s EPS forecast?

Monopar Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.38, marking a -99.42% decrease from the reported $-411 in 2024. Estimates for the following years are $-1.48 in 2026, $0.53 in 2027, and $1.86 in 2028.

What is Monopar Therapeutics’s revenue forecast?

Monopar Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $14.52M, followed by $42.5M for 2027, and $70.72M for 2028.

What is Monopar Therapeutics’s net income forecast?

Monopar Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-34.533M, representing a -99.78% decrease from the reported $-15.586B in 2024. Projections indicate $-15.836M in 2026, $-8.525M in 2027, and $26.99M in 2028.